EE537 How Good Are Cost-Effectiveness Model Predictions When Compared to Longer Follow-up Data? An Example of Nivolumab Studies in the First-Line Gastro-Oesophageal Setting
Abstract
Authors
R. Young T. Krieger R. Sharma G. Okorogheye B. Jones